Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Hemorrhage, Bariatric Surgery, Obesity, Morbid

In brief

The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are: Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding. Participants will: Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery

Key facts

Study ID

NCT07098780

Run by

Patel Hospital, Pakistan

People needed

140

Starts

2023-06-12

Expected to finish

2025-08-31

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients above 18 years of age AND
• Undergoing Laparoscopic Sleeve Gastrectomy and MGB
• Morbid obesity

You may not qualify if…

• Patients on anti-platelets/anti-coagulants
• Patients with inherited or acquired bleeding disorders
• Patients with any acute medical condition predisposing to bleeding
• Hormonal contraceptives
• Known Allery to TXA
• Female hormonal replacement therapy

Where it is running

• Patel Hospital — Karachi, Sindh, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.